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Seed viruses used to produce inactivated H5N1 influenza vaccines are recombinant viruses with modified avirulent-type hemagglutinin (HA) and
intact neuraminidase (NA) genes, both derived from an H5N1 isolate, and all remaining genes from the PR8 strain, which grows well in eggs.
However, some reassortants grow suboptimally in eggs, imposing obstacles to timely, cost-efficient vaccine production. Here, we demonstrate that
our PR8 strain supports better in ovo growth than the PR8 strain used for the WHO-recommended seed virus, NIBRG-14. Moreover, inclusion of an
alternative NA protein further enhanced viral growth in eggs. These findings suggest that our H5N1 vaccine candidates would increase the
availability of H5N1 vaccine doses at the onset of a new pandemic.
© 2007 Elsevier Inc. All rights reserved.Keywords: H5N1 influenza; Pandemic; VaccineIntroduction
The spread of H5N1 influenza Aviruses from Asia to Europe
and Africa, and the growing fatality toll continues to raise
concerns over a possible influenza pandemic (Horimoto and
Kawaoka, 2005), thus accelerating efforts to develop effective
H5N1 vaccines (Wood and Robertson, 2004). Because patho-
genic H5N1 viruses grow poorly in embryonated chicken eggs
(the approved vessel for influenza vaccine production) and pose
serious biosafety hazards, a number of candidate vaccine viruses
produced by reverse genetics have been generated, including
nonpathogenic recombinant viruses that possess modified
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remaining genes derived from a donor virus that grows well in
eggs (Horimoto et al., 2006; Nicolson et al., 2005; Subbarao
et al., 2003; Webby et al., 2004; Wood and Robertson, 2004).
The World Health Organization (WHO) recommends A/Puerto
Rico/8/34 (H1N1; PR8) as a donor strain because of its safety in
humans (Wood and Robertson, 2004), but recombinant viruses
do not grow as well in eggs as the original donor PR8 strain, even
though they possess the same “internal” genes (i.e., those other
than HA and NA) (Horimoto et al., 2006). This restriction
compromises timely, cost-efficient vaccine production. Further-
more, the limited immunogenicity of H5N1 human vaccines
requires higher amounts of H5 antigen than that used for annual
vaccination against non-H5N1 influenza virus subtypes (Trea-
nor et al., 2006). Therefore, a seed virus with more robust growth
in eggs is needed to ensure an adequate supply of H5N1 in-
fluenza vaccine, should a pandemic occur. To address this need,
we assessed the molecular basis of the growth of vaccine seed
virus in eggs, and propose a construct for the vaccine seed virus
with enhanced growth.
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The NIBRG-14 carrying the A/Vietnam/1194/2004 (H5N1;
VN1194) mHA and VN1194 NA genes and its remaining genes
from PR8(Cambridge) strain (George Brownlee, personal
communication) is a WHO-recommended seed virus for H5N1
inactivated vaccine now being tested in human clinical trials
(Dennis, 2006). The PR8 strain used to provide the genes other
than the HA and NA of the H5N1 vaccine seed strains was
isolated in 1934. Since then, it has been maintained in different
laboratories and differs in its growth properties depending on
how it has been maintained. Consequently, the growth of seed
viruses is likely affected by the PR8 strain used. Therefore, we
generated a reassortant (designated PR8UW/1194-H5N1),
possessing the mHA and NA identical to those of the NIBRG-
14 (i.e., VN1194 mHA and VN1194 NA) and the remaining
genes from the PR8(UW) strain maintained in our laboratory and
compared its in ovo growth with that of NIBRG-14. Interest-
ingly, we found that the growth of PR8UW/1194-H5N1 was
significantly better than that of the NIBRG-14 (Fig. 1A),
suggesting that our PR8(UW) strain would be superior to PR8
(Cambridge) for vaccine production in eggs. Moreover,
replacing the HA and NA of PR8UW/1194-H5N1 with those
of another WHO-recommended strain (A/Vietnam/1203/2004;
VN1203) further enhanced in ovo viral growth (Fig. 1A),
indicating the contribution of HA and NA to this property.
To address the molecular mechanism for the superior in ovo
growth of PR8(UW) relative to PR8(Cambridge), we construc-
ted a series of reassortants between PR8UW/1194-H5N1 andFig. 1. Growth of PR8/H5N1 reassortant viruses in chicken embryonated eggs. (A)
H5N1, and PR8UW/1203-H5N1 were determined at 48 or 60 h post-inoculation (hpi)
N3 eggs inoculated with each virus. Viruses with significant growth enhancement c
shown by an asterisk (∗). (B) Virus titers of reassortants containing mHA from eithe
(strain name-N1) were determined. The data are reported as mean titers and standard d
enhancement compared with PR8UW/1194-H5N1 (•) (pb0.05) were shown by an a
values to that of NIBRG-14. The data were determined as mean values and standard d
of the HA concentration compared with that of NIBRG-14 (•) (pb0.05) are shownNIBRG-14 by reverse genetics and tested their growth (Fig. 2).
Although two of six single-gene-reassortants showed signifi-
cantly lower plaque titers than PR8UW/1194-H5N1, their titers
were still higher than that of NIBRG-14. By contrast, simul-
taneous replacement of the polymerase and nucleoprotein (NP)
genes of PR8UW/1194-H5N1 with those of NIBRG-14 (see
multiple-gene ressortants, Fig. 2) resulted in a decrease in virus
titers to a level equivalent to NIBRG-14.We, therefore, conclude
that the polymerase subunit proteins and NP in concert are
responsible for the improved growth of PR8(UW) relative to
PR8(Cambridge).
Although the titer of a single gene reassortant possessing the
PR8(Cambridge) NS gene was higher than that of PR8UW/
1194-H5N1 when titrated with MDCK cells by a plaque assay,
this was not the case in eggs (Fig. 2); this increase in virus titers
with MDCK does not, therefore, appear to be useful for vaccine
production in eggs.
The HA–NA functional balance has been reported to affect
the growth in eggs of seed viruses for influenza seasonal
vaccines (Lu et al., 2005). Therefore, we next generated a series
of reassortant viruses bearing the VN1194 mHA, the remaining
genes other than NA from PR8(UW), and NA from the
following N1 strains: VN1203, A/Hong Kong/213/2003
(H5N1; HK213), A/Hong Kong/486/1997 (H5N1; HK486),
A/WSN/33 (H1N1; WSN), A/Kanagawa/173/2001 (H1N1;
Kanagawa), and PR8(UW). Among these reassortants, only
the virus with PR8(UW) NA showed significantly enhanced
growth compared to the PR8UW/1194-H5N1 virus (Fig. 1B).
Similarly, we generated reassortant viruses bearing VN1203Viral titers (EID50/ml) of the WHO-recommended NIBRG-14, PR8UW/1194-
for comparison. The data are reported as mean titers and standard deviations for
ompared with NIBRG-14 (•) (pb0.05, Student t-test with two-tail analysis) are
r VN1194 (1194-H5) or VN1203 (1203-H5) and NA from a different N1 virus
eviations for N3 eggs inoculated with each virus. Viruses with significant growth
sterisk (∗). (C) HA concentrations of the selected reassortants are shown as ratio
eviations in four independent experiments. Viruses with significant enhancement
by an asterisk (∗).
Fig. 2. Growth of PR8/H5N1 reassortant viruses containing heterologous internal genes, each derived from either PR8(UW) or PR8(Cambridge), in chicken
embryonated eggs. All viruses possess mHA and NA, both derived from VN1194. Virus titers were determined in eggs (EID50/ml) and a plaque assay with MDCK
cells (PFU/ml) and are shown as mean titers with standard deviations. Significantly decreased or increased titers compared with that of the PR8UW/1194-H5N1 virus
(underlined) (pb0.05) are shown by an asterisk (∗).
Table 1
Amino acid differences in internal proteins between PR8 strains
Protein Amino acid difference [Cambridge/UW(position)]
PB2 M/I(105), K/R(251), K/R(299), S/Y(360), V/I(504), R/K(702)
PB1 K/N(175), I/M(205), R/K(208), G/S(216), R/I(563)
PB1-F2 K/R(59), Q/R(60)
PA R/K(158), L/I(550)





25Rapid CommunicationmHA, the different NAs, and the remaining genes from PR8
(UW). Notably, the virus with PR8(UW) NA showed the highest
growth of all of the viruses tested. A greater than 20-fold en-
hancement of growth was observed with the virus containing
VN1203 mHA and PR8(UW) NA compared to PR8UW/1194-
H5N1, and a greater than 70-fold growth enhancement
compared to NIBRG-14 (Fig. 1B).
The comparative experiments described above were all con-
ducted at 37 °C, raising the possibility that differences in growth
among the test viruses may be influenced by temperature. In
further experiments, we found that PR8UW/1194-H5N1 grew
better at 33 °C than at 37 °C by 2.2-fold (p=0.048), whereas the
growth of NIBRG-14 and of the reassortant containing the 1194
mHA and PR8 NA showed essentially the same growth at both
temperatures (data not shown). Thus, the potential superiority of
PR8(UW) relative to PR8(Cambridge) for vaccine production is
independent of culture temperatures within 33 °C to 37 °C.
To evaluate whether enhanced growth in eggs correlates with
an increase in HA antigens for vaccine production, we purified
each reassortant from an equal amount of allantoic fluid (30 ml),
following virus propagation for 48 h at 33 °C, and measured the
HA concentration of each virus. Compared to the reference
NIBRG-14, significantly higher (2.7- to 5.1-fold) HA concen-
trations were evident for our reassortants (Fig. 1C), indicating
that more HA doses of H5N1 inactivated vaccines could be
manufactured from a given number of eggs using our seed
viruses than with NIBRG-14.
Discussion
In this study, we produced H5N1 influenza vaccine seed
viruses with enhance growth in chicken embryonated eggs.Seed viruses such as these, with more robust in ovo growth
potential, are needed to ensure an adequate supply of H5N1
influenza vaccine, for pre-pandemic and pandemic use. We
demonstrated that the PR8(UW) strain maintained in our
laboratory is a superior donor virus for H5N1 vaccine pro-
duction compared to the PR8(Cambridge) used to produce the
reference NIBRG-14 seed virus, with respect to in ovo growth.
PR8 strains differ in their growth properties depending on their
passage histories in a laboratory; PR8(UW) may be more highly
adapted in eggs than PR8(Cambridge). Since the high growth
property in eggs of PR8(UW) was determined by polymerases
and NP (Fig. 2), several mutations in these internal genes (as
shown in Table 1) may be responsible in concert for this optimal
growth adaptation.
Here, we found that HA–NA functional balance determined
growth of the vaccine seed viruses in eggs. The WHO re-
commends that 6:2 reassortant viruses containing mHA and NA,
derived from H5N1 viruses, and the remaining genes from PR8
be used as seed viruses for H5N1 inactivated vaccine production
26 Rapid Communication(Wood and Robertson, 2004). However, we demonstrated that
7:1 reassortant viruses containing only mHA from H5N1
viruses (and PR8 NA) grew significantly better than 6:2
reassortant viruses. One might argue that reassortants lacking
NA from an H5N1 isolate would induce a less protective
immune response than recombinant viruses with the H5N1 NA,
because of antigenic differences in these proteins (even though
the NA of PR8 is of the N1 subtype) (Chen et al., 2000;
Kilbourne et al., 1968). However, since HA is the major
protective antigen in inactivated vaccines, the enhanced growth
potential conferred by the PR8 NA should offset the limited
antigenic mismatch in this minor protective antigen. In the event
of a pandemic caused by a highly pathogenic avian influenza
virus, chicken eggs will likely be in short supply. Under such
conditions, a reassortant seed vaccine carrying the PR8 NA
would offer an attractive option for the generation of H5N1
vaccines.
In conclusion, we propose that, in addition to the 6:2 re-
assortant viruses recommended by the WHO, 7:1 reassortant
viruses (containing only a modified H5 derived from circulating
strains) in the background of the PR8(UW) strain may be
considered as vaccine seeds for H5N1 inactivated vaccine
production. This approach would allow the production of more




Madin-Darby canine kidney (MDCK) cells were grown in
Eagle's minimal essential medium (MEM) with 5% newborn
calf serum. African green monkey Vero WCB cells, approved
for use in human vaccine production (Sugawara et al., 2002),
were maintained in serum-free VP-SFM medium (GIBCO-
BRL) with antibiotics. Cells were maintained at 37 °C in 5%
CO2. The VN1194 and VN1203 H5N1 strains were propagated
in 10-day-old embryonated chicken eggs for 2 days at 37 °C,
after which time the allantoic fluids containing virus were
harvested. All experiments with infectious H5N1 viruses were
carried out in a Biosafety Level 3 containment laboratory. The
WHO-recommended vaccine seed virus, NIBRG-14 (PR8/
VN1194 6:2 reassortant) (Dennis, 2006), a kind gift from Drs.
John Wood and James Robertson, National Institute for
Biological Standards and Control, UK, was propagated once
in eggs for further experiments.
Generation of vaccine seed viruses
To generate reassortant viruses, we used plasmid-based re-
verse genetics (Neumann et al., 1999). Viral RNA from VN1194
or VN1203 was extracted from allantoic fluid by using a com-
mercial kit (ISOGEN LS, Nippon Gene) and was converted to
cDNA by using reverse transcriptase (SuperScript III; GIBCO-
BRL) and primers based on the consensus sequences of the 3-
prime ends of the RNA segments for the H5 viruses. The full-
length cDNAs were then PCR-amplified with ProofStartpolymerase (QIAGEN) and H5 subtype-specific primer pairs,
and cloned into a plasmid under the control of the human/mouse
polymerase I promoter/terminator (referred to as PolI plasmids),
generating a PolI-VN1194/HA or a -VN1203/HA construct
containing each HA gene. By using an inverse PCR method, we
altered the HA cleavage site sequence (RERRRKKR) of the
wild-type virus to create the avirulent-type sequence (RETR), as
described previously (Horimoto et al., 2006). We similarly
constructed PolI-VN1194NA and VN1203NA, containing each
NA gene, by the same procedure with N1-specific primers. Six
pPolI plasmids each containing an internal gene of PR8
(Cambridge) were constructed from NIBRG-14. Primer se-
quences are available upon request. We also used our previously
produced PolI plasmids, derived from WSN, PR8(UW),
HK213, HK486, and Kanagawa strains for reverse genetics
(Hatta et al., 2001; Horimoto et al., 2006; Kobasa et al., 2004;
Neumann et al., 1999). Using these PolI plasmids, we
conducted reverse genetics (12-plasmid) systems (Neumann et
al., 1999). Briefly, a total of 12 plasmids containing 8 PolI and 4
plasmids expressing PR8(UW) NP, PA, PB1, or PB2 under
control of the chicken β-actin promoter were transfected to Vero
cells with an electroporator (Amaxa) according to the manu-
facturer's instructions. Sixteen hours after transfection, freshly
prepared Vero cells were added to the transfected cells and, 6 h
later, TPCK-trypsin (1 μg/ml) was added to the culture, which
was then incubated for 4 days in serum-free medium. Super-
natants containing infectious viruses were harvested, biologi-
cally cloned once by limiting dilution in embryonated eggs, and
used in further experiments.
HA concentration of vaccine seed viruses
Viruses were purified through 25% sucrose from the allantoic
fluid of eggs by ultracentrifugation. Pellets were resuspended in
phosphate-buffered saline. For standardization of the HA
content, the protein concentration of the purified viruses was
measured by using a Micro BCA Protein assay kit (PIERCE).
Viral proteins were then separated by SDS-polyacrylamide gel
electrophoresis on a 10–20% gel and stained with Coomassie
brilliant blue. The gel image was captured and analyzed by using
a CS analyzer (ATTO, Tokyo), and the ratio of HA protein to
total protein was determined.
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